Cetera Investment Advisers Buys 52,988 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• Cetera Investment Advisers increased its holdings in Johnson & Johnson by 8.1% during the first quarter, owning 708,973 shares worth approximately $117.58 million.
• Analysts have set a new average price target of $174.50 for Johnson & Johnson, with varying ratings reflecting a mix of buy, hold, and outperform ratings.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, representing an annualized yield of 3.09% and a payout ratio of 55.61%.

Cetera Investment Advisers boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 708,973 shares of the company's stock after purchasing an additional 52,988 shares during the quarter. Cetera Investment Advisers' holdings in Johnson & Johnson were worth $117,576,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in JNJ. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Hudson Value Partners LLC increased its stake in shares of Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares during the period. Segall Bryant & Hamill LLC increased its stake in shares of Johnson & Johnson by 1.0% during the fourth quarter. Segall Bryant & Hamill LLC now owns 36,670 shares of the company's stock valued at $5,303,000 after buying an additional 367 shares during the period. Financial Engines Advisors L.L.C. increased its stake in shares of Johnson & Johnson by 14.4% during the fourth quarter. Financial Engines Advisors L.L.C. now owns 10,666 shares of the company's stock valued at $1,543,000 after buying an additional 1,340 shares during the period. Finally, Ausdal Financial Partners Inc. increased its stake in shares of Johnson & Johnson by 5.7% during the fourth quarter. Ausdal Financial Partners Inc. now owns 9,828 shares of the company's stock valued at $1,421,000 after buying an additional 527 shares during the period. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Raymond James Financial reduced their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Price Performance

NYSE JNJ traded down $1.22 during trading on Monday, hitting $167.08. 2,199,726 shares of the stock traded hands, compared to its average volume of 9,052,548. The company has a market capitalization of $402.01 billion, a P/E ratio of 17.86, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41. The firm has a 50-day simple moving average of $156.08 and a 200-day simple moving average of $155.97. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.82 EPS. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.11%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.